Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;6(3):118-124.
doi: 10.15420/aer.2017.20.1.

Limitations and Challenges in Mapping Ventricular Tachycardia: New Technologies and Future Directions

Adam J Graham  1 , Michele Orini  1   2 , Pier D Lambiase  1   2
Affiliations

Limitations and Challenges in Mapping Ventricular Tachycardia: New Technologies and Future Directions

Adam J Graham et al. Arrhythm Electrophysiol Rev. 2017 Aug.

Abstract

Recurrent episodes of ventricular tachycardia in patients with structural heart disease are associated with increased mortality and morbidity, despite the life-saving benefits of implantable cardiac defibrillators. Reducing implantable cardiac defibrillator therapies is important, as recurrent shocks can cause increased myocardial damage and stunning, despite the conversion of ventricular tachycardia/ventricular fibrillation. Catheter ablation has emerged as a potential therapeutic option either for primary or secondary prevention of these arrhythmias, particularly in post-myocardial infarction cases where the substrate is well defined. However, the outcomes of catheter ablation of ventricular tachycardia in structural heart disease remain unsatisfactory in comparison with other electrophysiological procedures. The disappointing efficacy of ventricular tachycardia ablation in structural heart disease is multifactorial. In this review, we discuss the issues surrounding this and examine the limitations of current mapping approaches, as well as newer technologies that might help address them.

Keywords: Ventricular tachycardia; arrhythmia; cardiomyopathy; catheters; ripple mapping; substrate mapping.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Pier D Lambiase receives speaker fees, educational grants and research grants from Medtronic and Boston Scientific.

Figures

Figure 1:
Figure 1:. Example of Concealed Entrainment from the Middle of the VT Isthmus in a Patient with IHD
Figure 2:
Figure 2:. Bipolar Voltage of Epicardial Substrate in Patient with ARVC in LAO Projection
Figure 3:
Figure 3:. Wideband Cardiac MRI Showing Inferolateral Scar (left). Image on the Right is Prior to Application of Wideband Technology to Remove the Artefact Caused by the ICD Generator
Figure 4:
Figure 4:. Orion Basket Catheter Used with the RHYTHMIA System, Containing 64×0.4 mm2 Electrodes with 2.5 mm Centre-to-centre Spacing to Enable Higher-resolution Mapping
Figure 5:
Figure 5:. High-resolution Mapping of Sustained Monomorphic VT (right) and Electrograms from the Roving Catheter (left)
Figure 6:
Figure 6:. Posterior–anterior View of Epicardial Bipolar Voltage Map (left) Showing Extensive Epicardial Scar. Posterior–anterior View of ECG–I Map (CardioInsight system, Medtronic) Showing Site of Earliest Activation (Earliest White) of Ventricular Tachycardia in the Same Patient
See this image and copyright information in PMC

References

    1. Goldenberg I, Gillespie J, Moss AJ et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the multicenter automatic defibrillator implantation trial. Circulation. 2010;122(13):1265–1271. doi: 10.1161/CIRCULATIONAHA.110.940148. - DOI - PubMed
    1. Connolly SJ, Gent M, Roberts RS et al. Canadian Implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–1302. - PubMed
    1. Sweeney MO, Sherfesee L, DeGroot PJ et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7(3):353–360. doi: 10.1016/j.hrthm.2009.11.027. - DOI - PubMed
    1. Poole JE, Johnson GW, Hellkamp AS et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–1017. doi: 10.1056/NEJMoa071098. - DOI - PMC - PubMed
    1. Connolly SJ, Dorian P, Roberts RS et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165–171. doi: 10.1001/jama.295.2.165. - DOI - PubMed

LinkOut - more resources